APPLICATION
ANDA202402
TYPE
ANDA
ORIGINAL APPROVAL
2016-03-30
LATEST ACTION
2024-07-03
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
IBUPROFEN LYSINEPrescription
IBUPROFEN LYSINE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) · INJECTABLE · INTRAVENOUS
Approval history
2024-07-03Labeling · Supplement 5 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.